Soligenix (SNGX)
(Delayed Data from NSDQ)
$0.42 USD
-0.01 (-2.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.42 +0.01 (1.20%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Soligenix Inc. [SNGX]
Reports for Purchase
Showing records 81 - 98 ( 98 total )
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Termination of Coverage
Provider: RODMAN & RENSHAW, CO.
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
orBecs pivotal study terminated. Rating is Under Review.
Provider: RODMAN & RENSHAW, CO.
Analyst: HIGGINS M
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
orBecs pivotal study terminated. Rating is Under Review.
Provider: RODMAN & RENSHAW, CO.
Analyst: HIGGINS M
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Nets cash and a 40% royalty on orBecs EU rights, as Sigma Tau adds to their US rights.
Provider: RODMAN & RENSHAW, CO.
Analyst: HIGGINS M
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Soligenix nets cash and a 40% royalty on orBecs EU rights, as Sigma Tau adds to their US rights.
Provider: RODMAN & RENSHAW, CO.
Analyst: HIGGINS M
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
We are updating coverage with a BUY rating, and we are increasing our 12-month price target to $1.50
Provider: GRIFFIN SECURITIES, INC.
Analyst: BEDRIJ C
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Q111 results were in-line. Near-term, two pipeline assets may add value to this orBec story.
Provider: RODMAN & RENSHAW, CO.
Analyst: HIGGINS M
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Q111 results were in-line. Near-term, two pipeline assets may add value to this orBec story.
Provider: RODMAN & RENSHAW, CO.
Analyst: HIGGINS M
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Initiation: Soligenix shares poised to run higher on outlook.
Provider: RODMAN & RENSHAW, CO.
Analyst: HIGGINS M